Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay.
Arber
Caroline
C
Haematology, University Hospital Basel, Switzerland. arberc@uhbs.ch
Bertrand
Gerald
G
Halter
Jörg
J
Boehlen
Françoise
F
Kaplan
Cécile
C
Gratwohl
Alois
A
D000208:Acute Disease; D016824:Antigens, Human Platelet / Q000276:immunology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007518:Isoantibodies / Q000032:analysis*; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000628:therapy*; D008875:Middle Aged; D017713:Platelet Transfusion; D014184:Transplantation, Homologous; D017211:Treatment Failure
C071092:5a alloantigen, human; D016824:Antigens, Human Platelet; D006680:HLA Antigens; D007518:Isoantibodies